ClinicalTrials.gg
RecruitingNCT04713657Updated Oct 26, 2026

Beta-blocker Administration for Cardiomyocyte Division

A Phase 1 interventional study of N-thymidine and Urine Collection in Tetralogy of Fallot and Double Outlet Right Ventricle, sponsored by Weill Medical College of Cornell University. Recruiting at 4 sites in United States. Open to participants aged 30 Days to 100 Days. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Weill Medical College of Cornell University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Updated Oct 26, 2026Eligibility revised1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
30 Days to 100 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Tetralogy of Fallot with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Tetralogy of Fallot · United States.

Planned enrollment
10th of 20
40 · median 35
Started
2022
with 3 others
Phase 1
3 of 32
1 open now
Primary completion
2030-12
later than 11 of 11 live
Registered
23rd of 32
by date

Among the 32 studies in Tetralogy of Fallot with a site in United States, this one is the 10th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 1, reaches primary completion later than 11 of the 11 other live ones, and was the 23rd registered.

Tetralogy of Fallot

92 studies on the registry are indexed under Tetralogy of Fallot; 25 are open to participants now.

Browse Tetralogy of Fallot studies →

Open to participants now

7 of the 32 studies in Tetralogy of Fallot with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Tetralogy of Fallot studies recruiting now, 8 (47%) set no upper age limit and 9 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.

This study: 30 Days to 100 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Tetralogy of Fallot with a site in United States, or all of them as a file.
02

Study summary

Heart failure is a common long-term complication in patients with congenital heart disease (CHD). Medical treatments to promote regeneration of new healthy heart muscle cells have the potential to provide new heart failure treatments for these patients. The development of such therapies is limited by the poor understanding of the ways in which heart muscles grow after birth. Investigators have learned that humans without heart disease generate new heart muscles cells up to the age of 20 years old and that this is decreased in patients with congenital heart disease like Tetralogy of Fallot. Investigators are trying to determine if treatment with a medicine called Propranolol can increase heart muscle cell proliferation and, with that, normalize heart growth. Investigators will examine discarded heart muscle tissue that is obtained during surgery for the presence of new heart muscle cells. Propranolol is approved by the Food and Drug Administration (FDA) to treat a certain kind of benign tumor in infants (hemangioma), but it is not currently approved by the FDA to increase heart muscle growth.

03

Conditions studied

  • Tetralogy of Fallot
  • Double Outlet Right Ventricle

Browse trials for

Keywords

  • Tetralogy of Fallot
  • Double Outlet Right Ventricle
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
30 Days to 100 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female infants \< 100 days of age with a diagnosis of tetralogy of Fallot (ToF) with pulmonary stenosis (PS) or double outlet right ventricle (DORV), tetralogy type by echocardiogram, who weigh greater than 2 kg at the time of consent and are tolerating enteral feeds.
  • DORV variant

Exclusion criteria

Exclusion Criteria:

  • congenital atrio-ventricular block on (PR interval > 120 ms),
  • concomitant medication administration that interacts with propranolol,
  • patient family is, in the opinion of the investigator, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason,
  • Premature infants with corrected age \< 5 weeks,
  • asthma or underlying respiratory disease,
  • presence of metal implants in infants.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Propranolol

    The target dose of Propranolol hydrochloride for this study target dose for this study will be 1mg/kg PO x 3 doses per day. The concentration of propranolol solution is 20 mg/5 mL. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with propranolol will begin at 1 month of age and continue until 4 months of age or 24hrs prior to surgical repair, whichever comes first.

    Other: N-thymidine · Other: Urine Collection · Procedure: Echocardiogram · Procedure: Cardiac MRI (CMR) · Drug: Propranolol Hydrochloride · Procedure: Physical Exam · Other: Specimen Collection

  • Placebo comparator
    Placebo

    Placebo will be given in a volume that corresponds to the patient's weight. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with placebo will begin at 1 month of age and continue until 4 months of age or 24hrs prior to surgical repair, whichever comes first. There is no current standard of care for pharmacologic therapy for infants with Tetralogy of Fallot (ToF). As such, there are no alternative treatments, and the placebo group is standard of care.

    Other: N-thymidine · Other: Urine Collection · Procedure: Echocardiogram · Procedure: Cardiac MRI (CMR) · Drug: Placebo · Procedure: Physical Exam · Other: Specimen Collection

Interventions

  • OtherN-thymidine

    15N-thymidine will be administered to patients in order to quantify cardiomyocyte proliferation. 15N-thymidine will be administered as 5 separate syringes. Each syringe will contain the recommended daily dose based on participants weight. Subjects will be given the labeled thymidine by mouth once a day for 5 consecutive days. The dosing will begin one week after starting the study drug.The caregiver (parent or nurse) will administer the labeled thymidine by mouth via a syringe once a day for 5 consecutive days. They will be provided with a diary to keep track of study drug dosing.

    Also known as: Thymidine

  • OtherUrine Collection

    Parents will be asked to keep a diary of the child's feeding and diaper changes during the administration of thymidine. To monitor how the labeled thymidine is processed in the body, investigators will analyze urine from the child's diapers. Each time a diaper is changed, a cotton ball will be placed in the diaper. At the next diaper change, this cotton ball will be removed from the diaper, placed in a Ziploc bag, and stored in the freezer. They will be collected and stored cotton balls starting with the first administration of thymidine until 24 hours after the last administration. The frozen cotton balls may be collected from the home by a nurse or brought by parent to the next clinic visit.

  • ProcedureEchocardiogram

    On Study Day 1 to obtain baseline assessment of cardiac size. A second research dedicated echocardiogram will be done after being anesthetized for surgery. Echocardiography is routinely performed to determine right ventricle (RV) structure of the heart and function in Tetrology of Fallot/ Pulmonary Stenosis (ToF/PS) and is non-invasive.

  • ProcedureCardiac MRI (CMR)

    A limited study protocol will be performed using the feed-and-bundle technique at the time of study enrollment, The feed and bundle technique is utilized so that the infant will be as comfortable as possible and asleep during the procedure. This is done to prevent the risk of sedation and allow for a more natural sleep. The baby is undressed, prepared with ECG-leads and an oxygen saturation probe, and fed. With this "feed, swaddle, and sleep" technique, scanning times of 30-60 minutes can be achieved, which provides the stillness needed for accurate visualization of the heart. A second CMR, with the same limited study protocol, will be performed under general anesthesia prior to surgical repair. It does not pose any risk of radiation exposure and will not require IV placement or contrast administration for a limited assessement of the right ventricle.

  • DrugPropranololStudies of PropranololPropranolol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For patients who are randomized to receive propranolol, The target dose for this study will be 3 mg/kg/day divided in 3 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 3 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.

    Also known as: Propranolol

  • DrugPlacebo

    For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 3 doses per day. Treatment with placebo will begin at 1 month of age and continue until 4 months of age or 24hrs prior to surgical repair, whichever comes first.

  • ProcedurePhysical Exam

    On Study Day 1; monthly until surgery in conjunction with patient's clinical cardiology appointment; and at the time of surgery. Will include vital signs.

  • OtherSpecimen Collection

    On the morning of surgery, after IV access is obtained for anesthesia 2 ml of blood will be collected for analysis. A small piece of heart tissue and fat that has already been removed during surgery will be collected for analysis.

06

What researchers measure

Primary outcomes

  1. Cardiomyocyte Division

    To quantify cardiomyocyte division, investigators will utilize previously established MIMS (membrane introduction mass spectrometry) approach. Briefly, investigators will administer 5 enteral doses of 15N-thymidine to all patients at 1 month after birth. Cardiomyocytes that have undergone DNA replication after the intake of 15N-thymidine will incorporate the stable isotope into their DNA.

    Time frame: At the time of complete surgical repair, at approximately 3-9 months old, it is expected that a piece of RV myocardium will be resected. This tissue will be collected and analyzed using a multiple isotope mass spectrometer.

Secondary outcomes

  1. Hypertrophy as assessed by echocardiography

    Analysis of the impact of propranolol on Right Ventricle Myocardial Volume

    Time frame: At 1 month and at time of surgery

  2. Hypertrophy as assessed by Cardiac MRI

    Analysis of the impact of propranolol on Right Ventricle Myocardial Volume

    Time frame: At 1 month and at time of surgery

  3. Hypertrophy assessed by microscopy

    Analysis of the impact of propranolol on cardiomyocytes cross sectional area

    Time frame: At time of Surgery

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • El Khoudary SR, Fabio A, Yester JW, Steinhauser ML, Christopher AB, Gyngard F, Adams PS, Morell VO, Viegas M, Da Silva JP, Da Silva LF, Castro-Medina M, McCormick A, Reyes-Mugica M, Barlas M, Liu H, Thomas D, Ammanamanchi N, Sada R, Cuda M, Hartigan E, Groscost DK, Kuhn B. Design and rationale of a clinical trial to increase cardiomyocyte division in infants with tetralogy of Fallot. Int J Cardiol. 2021 Sep 15;339:36-42. doi: 10.1016/j.ijcard.2021.07.020. Epub 2021 Jul 12. PubMed 34265312 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Dec 2030, 96 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2021
First posted
Jan 19, 2021
StartActual
Dec 16, 2022
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Columbia University Morgan Stanley Children'S Hospital · New York, United States
Oct 26, 2026
Eligibility
Maximum age 60 Days→100 Days; 1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedMale and female infants < 60100 days of age with a diagnosis of tetralogy of Fallot (ToF) with pulmonary stenosis (PS) or double outlet right ventricle (DORV), tetralogy type by echocardiogram, who weigh greater than 2 kg at the time of consent and are tolerating enteral feeds.
Exclusion criteria
  • EditedgestationPremature infants with corrected age < 355 weeks,
  • Editedinfants of diabetic mothers, asthma or underlying respiratory disease,
Oct 26, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Upmc Children'S Hospital of Pittsburgh · Pittsburgh, United StatesContact person changed (no phone or email listed)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    1 site added
    Show site
    • Columbia University Morgan Stanley Children'S Hospital · New York, United States
    Eligibility Maximum age 60 Days→100 Days; 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedMale and female infants < 60100 days of age with a diagnosis of tetralogy of Fallot (ToF) with pulmonary stenosis (PS) or double outlet right ventricle (DORV), tetralogy type by echocardiogram, who weigh greater than 2 kg at the time of consent and are tolerating enteral feeds.
    Exclusion criteria
    • EditedgestationPremature infants with corrected age < 355 weeks,
    • Editedinfants of diabetic mothers, asthma or underlying respiratory disease,
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Upmc Children'S Hospital of Pittsburgh · Pittsburgh, United StatesContact person changed (no phone or email listed)
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04713657
Responsible party
Sponsor
First posted
Jan 19, 2021
Start date
Dec 16, 2022
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Rashida Blackwood, BS, MPH
Contact
rab4029@med.cornell.edu
646-962-9036
Bernhard Kuhn, MD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propranolol

Start the discussion